Sitemap
En
Press Release
Current Location: Home > Press Release > Investment News & Information

Novo Nordisk Has Continuously Increased Its Investment in TEDA

09-29-2022

A production line of anti-diabetes injection is pictured at a workshop of Novo Nordisk (China) Pharmaceutical Co., Ltd. in TEDA, Tianjin, Sept. 22, 2022.

Over the past 20 years, Novo Nordisk, a pharmaceutical company from Denmark, has continuously increased its investment in TEDA. Now, Novo Nordisk has already established a full value chain in the country, with one of its biggest manufacturing bases in Tianjin that supplies both Chinese and international markets with durable devices for insulin injection and insulin products.


Staff members work at a workshop of Novo Nordisk (China) Pharmaceutical Co., Ltd. in TEDA, Tianjin, Sept. 22, 2022.

A film wrapping robot carries out packaging operation at a workshop of Novo Nordisk (China) Pharmaceutical Co., Ltd. in TEDA, Tianjin, Sept. 22, 2022.

Website Identification Code: 1201160062

Are you sure you want to leave this page?